Find investors
← Back to all investors
BC
ResearchedAngel Investors

Ben Chou

Managing Director

Angel InvestorsSeed Round
Pitch Ben

Get their honest, personalized take on your startup.

Sign in to pitch Ben

At a glance

Full Name
Ben Chou
Title
Managing Director
Firm
Trans-Pacific Technology Fund (TPTF)
Firm Type
Venture Capital fund (note: the source stub labeled him "Angel Investors," but TPTF is an institutional, technology-focused VC firm founded in 2014; Chou also invests personally at the seed/angel stage)
Investment Stage
Seed and Series A
Check Size
~$1–5 million (firm level)
Target Company Profile
Early-stage companies building disruptive, platform-level technologies with cross-Pacific (US–Asia) commercialization potential; typical hold horizon of 3–5 years, exiting via strategic sale or IPO
Sector Focus
Advanced materials, health/life sciences, ICT, IoT, and robotics/automation (firm); Chou's personal areas are green technology, cloud computing, hardware components, and bio-medical
Geographic Focus
Asia, North America, and Europe — with an emphasis on cross-border deals spanning Silicon Valley, Hong Kong, China, and Taiwan
Location
Taipei, Taiwan

Background

Ben Chou is a Managing Director at the Trans-Pacific Technology Fund (TPTF), a Taipei-based, technology-driven venture capital fund founded in 2014 that backs innovation companies across Asia, North America, and Europe. In this role he leads cross-border technology investing, drawing on a career that spans both operating and investing roles across the US, Taiwan, and China.

Earlier in his career, Chou spent more than twelve years at Intel, working in the US, Taipei, and China. His responsibilities there ranged from design and application engineering, processor design, and manufacturing, through to heading the product and technical marketing team for the Asia-Pacific region — giving him a hands-on grounding in semiconductors and hardware before moving into finance.

He then transitioned into venture capital and private equity, serving as an Investment Manager at China Development Industrial Bank (CDIB) & Partners, where he focused on fund management and direct investments. Across roughly two decades in the technology and investing worlds, his work has centered on cross-border opportunities linking Silicon Valley with Greater China and Taiwan, with a recurring emphasis on green technology, cloud computing, hardware, and bio-medical companies.

Chou holds an M.S. in Management Information Systems from Boston University and a B.S. in Computer Science from National Chiao-Tung University (NCTU) in Taiwan.

Investment Thesis & Focus

  • Invests primarily at Seed and Series A, with firm check sizes generally in the $1–5 million range and a stated 3–5 year investment horizon.
  • Targets "disruptive, platform technologies" — TPTF's core sectors are advanced materials, health/life sciences, ICT, IoT, and robotics/automation.
  • Chou's personal thesis leans toward green technology, cloud computing, hardware components, and bio-medical industries.
  • Prizes cross-border, trans-Pacific plays: companies that can bridge US innovation (especially Silicon Valley) with manufacturing, scaling, and market access across Taiwan, China, and Hong Kong — an area where his Intel operating background and CDIB investing experience are directly relevant.
  • Plans exits via strategic sale to a corporate/strategic acquirer or IPO, consistent with the fund's institutional, returns-driven mandate.

Notable Investments

  • Apexigen — clinical-stage biopharmaceutical company developing next-generation antibody therapeutics for cancer (later went public via SPAC in 2022).
  • Finch Therapeutics — late clinical-stage microbiome company built on its Full-Spectrum/Selected Microbiota platforms.
  • Quanergy — LiDAR sensors and perception software for real-time 3D data capture.
  • Googol Technology — smart manufacturing, robotics, and industrial IoT solutions.
  • Kata.ai — conversational AI platform focused on the Bahasa (Indonesian) language.
  • Heal — AI- and data-driven primary care and doctor house-call platform.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.